BIOMARKER:

High MHC-II signature

News alerts, weekly reports and conference planners

High MHC-II signature	Bladder Cancer	High MHC-II signature	Bladder Cancer	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
High MHC-II signature	Bladder Cancer	High MHC-II signature	Bladder Cancer	NU7441 Sensitive: C3 – Early Trials NU7441 Sensitive : C3	NU7441 Sensitive: C3 – Early Trials NU7441 Sensitive : C3
High MHC-II signature	Bladder Cancer	High MHC-II signature	Bladder Cancer	docetaxel Sensitive: C3 – Early Trials docetaxel Sensitive : C3	docetaxel Sensitive: C3 – Early Trials docetaxel Sensitive : C3
High MHC-II signature	Bladder Cancer	High MHC-II signature	Bladder Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3

Associations